CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 6 enrolled
Drug / intervention
etanerceptdrug
Likely dose
etanercept 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01053819
NCT01053819Phase 4Completed

Can We Miss Pigmented Lesions in Psoriasis Patients?

University of Alabama at Birmingham·interventional·Posted Jan 21, 2010·Updated Feb 23, 2018

In Brief

A Phase 4 clinical trial evaluating etanercept for Psoriasis and 2 related conditions. Completed, enrolled 6 participants across 1 site.

Detailed Summary

In psoriasis patients, thick psoriatic plaques can obscure these lesions, and clinicians rely heavily on visual inspection to recognize suspicious or atypical pigmented lesions. However, successful systemic treatment and subsequent clearing of psoriatic plaques may allow clinicians to better evaluate pigmented lesions, thereby increasing the likelihood of early identification and treatment of suspicious lesions such as nonmelanoma skin cancer and malignant melanoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsAmgen

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 21, 2010
Enrollment StartSep 1, 2007
Primary CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 16.4 years ago

Interventions

etanerceptdrug

Patients will receive six months of treatment with Enbrel 50mg SQ given twice a week for the first three months and 50 mg once a week thereafter.